Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer IND
Eikon Therapeutics disclosed updated lung cancer data, a registrational trial start, and an IND filing for a new prostate cancer drug, alongside $461.7 million in cash.
SEC filing (12)